We make a programme with different theme every year to improve the patient's medical experience and enable patients to have a better hospitalized experience. We have a deep understanding of the patient's needs, walked into the patient's heart, and give
the patient more psychological support and meet the needs of patients beyond expectation,which help to fulfill themselves.
</div>
<divclass="contant_center">
<divclass="contant_one">
<divclass="contant_img">
<aclass="single_mark"href="profession.html">
<imgsrc="../images/5-2-15.png"alt=""/>
</a>
</div>
<divclass="contant_center_title">
The nurse’s smile brought warmth to the patient
</div>
</div>
<divclass="contant_one">
<divclass="contant_img">
<aclass="single_mark"href="profession.html">
<imgsrc="../images/5-2-16.png"alt=""/>
</a>
</div>
<divclass="contant_center_title">
Happy Children’s Day
</div>
</div>
<divclass="contant_one">
<divclass="contant_img">
<aclass="single_mark"href="profession.html">
<imgsrc="../images/5-2-17.png"alt=""/>
</a>
</div>
<divclass="contant_center_title">
Nurses in digestive cancer department send love to patients in Lantern Festival
</div>
</div>
<divclass="contant_one">
<divclass="contant_img">
<aclass="single_mark"href="profession.html">
<imgsrc="../images/5-2-18.png"alt=""/>
</a>
</div>
<divclass="contant_center_title">
The nurse in Pulmonary Medical Department have a nice talk with the patient
Director Nurse of Tianjin Medical University Cancer Institute & Hospital, Postgraduate tutors of Tianjin Medical University and Tianjin University of Traditional Chinese Medicine
We have established 10 professional groups . They carry out a series of activity based on the patient's needs and cooperate multidisciplinary to lead and improve the development of cancer care
</div>
<divclass="contant_center">
<divclass="contant_word">
<divclass="contant_one">
<divclass="contant_one_img">
<imgsrc="../images/5-2-1.png"alt=""/>
</div>
<divclass="contant_one_title">
Professional Activities of the Psychological Support team
Tianjin Cancer Institute<span>></span>About Us<span>></span>About Us
</div>
<divclass="contant">
<divclass="contant_one">
Tianjin Cancer Institute was established in 1977 by the late Chinese oncologist Professor Jin Xianzhai. It used to be the Cancer Prevention Research Laboratory of Tianjin People’s Hospital. In 1987, Tianjin People’s Hospital was renamed Tianjin Cancer
Hospital, and the Research Laboratory was set as an institute. In 1997, the Cancer Hospital and Research Institute were assigned to Tianjin Medical University. In 2007, the Institute became an independent legal entity. Jin Xianzhai,
Zhou Yanchang, Zhang Tianze and Jin Jiarui have served as the director of has served as the director successively. Academician Hao Xishan is the current director, with Professor Ying Guoguang, Professor Niu Ruifang and Professor Li
Hui acting as the deputy directors.
</div>
</div>
<divclass="contant_img">
<imgsrc="../images/71.png"alt=""/>
</div>
<divclass="contant_one">
Tianjin Cancer Institute has 12 departments, namely the Laboratory for Cancer Epidemiology & Biostatistics, the Laboratory for Pathology, the Laboratory for Biochemistry & Molecular Biology, the Laboratory for Cancer Cell Biology, the Laboratory for Immuno-Biotechnology,
the Laboratory for Gastrointestinal Tumor Biology, the Pharmacology Laboratory, the Public Laboratory, the Tumor Molecular Diagnostic Center, the Tissue Bank, the Library and the Editorial Department.<br/>Relying on the
discipline of oncology which is the national key discipline, Tianjin Medical University became a national first-class discipline construction university in 2017, and the clinical medicine (basics and clinical discipline of tumors) is the
discipline to be constructed. It has the Key Laboratory of Breast Cancer Prevention and Control directly under the Ministry of Education, the Tianjin Municipal Key Laboratory of Cancer Prevention and Control, the Tianjin Municipal Key
Laboratory of Cancer Immunity and Biotherapy, and positions of the “Changjiang Scholars and Innovation Team Development Plan” of the Ministry of Education. Having focused on oncology basic research and clinical transformation application
research for years, the Institute lays emphasis on the prevention, early diagnosis and individualized clinical treatment of tumor diseases. Our main research directions include tumor epidemiology, tumor pathology and molecular typing,
tumor genesis, tumor immunity and immunotherapy. The Institute has made a series of achievements and progress in establishing a three-level prevention and control model for the common malignant tumors in China, screening high-risk populations,
discovering new tumor-related genes, exploring tumor development mechanisms, and the R&D of new theory about the tumor angiogenesis, the new methods of tumor diagnosis, and the new technologies for tumor immunotherapy.
</div>
<divclass="contant_img">
<imgsrc="../images/72.png"alt=""/>
</div>
<divclass="contant_one">
In the past 5 years, the Institute has obtained 83 scientific research projects at and above the provincial and ministerial level, including 3 National Key Technology Research and Development Programs of the Ministry of Science and Technology of China
and 55 programs supported by the National Natural Science Foundation of China. Besides, the Institute has published altogether 314 SCI papers. Since the 12th Five-Year Plan was implemented, the Institute has been awarded a total of 6 scientific
and technological achievements at and above the provincial and ministerial level. Moreover, Academician Hao Xishan was given the Science and Technology Major Achievement Prize of Tianjin in 2011. <br/> With the aim of
consolidating and improving the level of the discipline construction, the Institute has been continuously strengthening the construction of its talent teams. The Institute currently has a total of 179 professional technical personnel at
various levels, including 1 academician of the Chinese Academy of Engineering, 1 foreign academician of the Chinese Academy of Engineering, 1 Distinguished Young Scholar of the National Natural Science Foundation of China, 4 special lecturers
of the Chang Jiang Scholars Program of the Ministry of Education, 1 leading talent of the Ten Thousand Talent Program, 1 person of Millions of Talents in the Ministry of Human Resources and Social Security, 1 talent of the National Special
Support Program for High-level Personnel Recruitment, 1 leader of the “Changjiang Scholars” Innovation Team, 2 personnel supported by the Ministry of Education’s Program for New Century Excellent Talents, 2 Outstanding Mid-aged Experts
awarded by the Ministry of Health, 1 “131” Innovative Talent Team of Tianjin, 5 specially-appointed professors of Tianjin, 5 people supported by the “Thousand Talent Program” of Tianjin, and 4 “131” Innovative Talents of Tianjin at the
first level. <br/> The Institute has implemented a management system based on current principle investigators（PIs）since 2013, We currently has 17 full-time PIs with their research teams. There are 24 doctoral tutors and 37 master tutors.
In the past 5 years, the Institute has recruited a total of 62 doctoral students, 124 postgraduate students. In additions, there are 64 graduated doctoral students and 86 graduated postgraduate students. <br/> We have been attaching the
great importance to the construction of the core facilities and services. In order to provide a strong support for the high-level researches to be carried out, the Institute has built the Tissue Bank, the Tumor Molecular Diagnostic Center,
the Large-Scale instrument platform, the bioinformatics platform, the Pharmacology Laboratory, the clinical drug evaluation, and the SPF experimental animal platform. <br/> The Institute will closely continue tracking the international
frontier trends in the research field of the oncology and the translational medicine, and emphasizing the original and independent innovation of the theory and the technology, so as to cultivate more senior personnel for the oncology research
and medical development of China, and make the positive contributions to comprehensively improve the ability of preventing and treating cancer of China.
</div>
</div>
<footerclass="footer-content">
<divclass="footer-main">
<ulclass="list-unstyled third-ul">
<li>West Huan-Hu Rd, Ti Yuan Bei, Hexi District</li>
Tianjin Cancer Institute<span>></span>Research<span>></span>Core Facilities and Services<span>></span>Public Laboratory
</div>
<divclass="contant">
<divclass="contant_img">
<imgsrc="../images/ins_top.png"alt=""/>
</div>
<divclass="contant_center">
<divclass="contant_title">Introduction</div>
<divclass="contant_word">
In line with Tianjin medical university cancer hospital’s overall teaching and research development objectives, to strengthen and enhance the fundamental and applied research, to cultivate top-notch creative talent, and to ensure that the available research
resources will be efficiently used, our hospital organized and set up in 2009Public Experimentation Center, located on thesixth floor of Building C. After several years of investment and construction, and relying on the strengths
of our faculty and technology, our centerhave evolved into a comprehensive research center dotted with logical organization, high efficiency, opening-up, and advanced technology. The center consists of four technical service-orientedplatforms,
i.e., the core facility and technical service Platform, the Clinical Laboratory, the SPF Animal Laboratory andtheBioinformatics Platform.The center covers an area of about 2000 m2, the value is worth over 50 million RMB. Now, the
Public Laboratory is not only an important experimental base for conducting scientific research and translational medicine research, but also a supporting platform for cultivating top-notch creative medical talent.
</div>
<divclass="contant_words">
Services
</div>
<divclass="contant_one">
<divclass="contant_one_img">
<imgsrc="../images/77.png"alt=""/>
</div>
<divclass="contant_one_title">
1. The core facility and technical service platform is funded by Tianjin medical university cancer institute & hospital. The establishment of this platform will provide centralized and expertise support to our colleagues requiring these advanced technology
platforms in their research studies. It will enhance effective usage of resources and maximize the use of expensive instruments required for these advanced technology platforms. The platform is equipped with Laser Scanning
Confocal Microscope, Flow Cytometer, Upright Fluorescent Microscope, Inverted Fluorescent Microscope, Real-Time PCR apparatus, Ultra-Centrifuge and so on.The appointments software (LIMS) has been used deeply along with the
servicesto enhance service abilityand to improve the service efficiency.
</div>
</div>
<divclass="contant_one">
<divclass="contant_one_img">
<imgsrc="../images/78.png"alt=""/>
</div>
<divclass="contant_one_title">
2. The clinical laboratory is a research platform for translational medicine. The objective of the clinical laboratory is to provide multidisciplinary scientists from different faculty of TJMUCH a synergistic platform which efficiently and effectively
translate basic scientific findings into knowledge that benefits patients, which is often described as an effort to carry scientific knowledge ‘from bench to bedside’. At present, we have 17 different research groups at the
clinical laboratory, all of which engage in cutting-edge research. The research group (under the management of principal investigator) is a group of researchers or students from the same faculty working together on a particular
issue or topic. In this way we hope to stretch boundaries, challenge traditional ways of thinking, and innovate towards finding new solutions to problems. Now, the clinical laboratory is home to world-class research facilities,
a specialist clinical trials unit and a suite of molecular biology laboratories.
</div>
</div>
<divclass="contant_one">
<divclass="contant_one_img">
<imgsrc="../images/79.png"alt=""/>
</div>
<divclass="contant_one_title">
3. The SPF Animal Laboratory, with a total floor area of about 500 m2, is a comprehensive service entity involved in research of Laboratory Animal Science, providing technical support and services for animal research. It includes SPF (Specific-pathogen-free)
barrier environment, conventional environment and functional auxiliary environment. Relevant environmental facilities obtained the experimental animal use license (SYXK (Tianjin) 2012-0005) issued by Tianjin Municipal Science
and Technology Commission in 2012, and successfully replaced the new experimental animal use license (SYXK (Tianjin) 2017-0005) in 2017, providing a strong guarantee for the scientific research of our discipline.Our staff provides
daily animal care for the 15,000 animals used in research and teaching hospital-wide. Our goal remains to support the needs of our biomedical research community by providing an optimal environment for their animals and research.
</div>
</div>
<divclass="contant_one">
<divclass="contant_one_img">
<imgsrc="../images/80.png"alt=""/>
</div>
<divclass="contant_one_title">
4. Our research focuses on characterizing mutational landscape of human gastrointestinal cancer, elucidating the association between mutational footprints and environmental factors, identifying biomarkers with translational significance in immunotherapy
and early cancer diagnosis, and interpreting medical imaging data using deep learning algorithms. Through bioinformatics analyses, we identified new driver genes underlying the development of gastrointestinal cancer, and shed
new lights on genetic markers that are potentially clinically actionable. By applying deep learning algorithm to analyze large-scale sonographic imaging data, we developed a deep learning model that could augment radiologists’
ability in thyroid cancer diagnosis. We have published more than 20 peer-reviewed articles in international journals, including Lancet Oncology, JAMA Oncology, and Annals of Oncology etc.
In line with Tianjin medical university cancer hospital’s overall teaching and research
development objectives, to strengthen and enhance the fundamental and applied research, to
cultivate top-notch creative talent, and to ensure that the available research resources
will be efficiently used, our hospital organized and set up in 2009Public Experimentation
Center, located on thesixth floor of Building C.
After several years of investment and construction, and relying on the strengths of our
faculty and technology, our centerhave evolved into a comprehensive research center dotted
with logical organization, high efficiency, opening-up, and advanced technology.
The center consists of four technical service-orientedplatforms, i.e., the core facility
and
technical service Platform, the Clinical Laboratory, the SPF Animal Laboratory
andtheBioinformatics Platform.The center covers an area of about 2000 m2, the value is
worth
over 50 million RMB.
Now, the Public Laboratory is not only an important experimental base for conducting
scientific research and translational medicine research, but also a supporting platform for
cultivating top-notch creative medical talent.
<h3>Introduction</h3> <br> In line with Tianjin medical university cancer hospital’s overall teaching and research development objectives, to strengthen and enhance the fundamental and applied research, to cultivate top-notch creative
talent, and to ensure that the available research resources will be efficiently used, our hospital organized and set up in 2009Public Experimentation Center, located on thesixth floor of Building C. After several years of investment
and construction, and relying on the strengths of our faculty and technology, our centerhave evolved into a comprehensive research center dotted with logical organization, high efficiency, opening-up, and advanced technology.
The center consists of four technical service-orientedplatforms, i.e., the core facility and technical service Platform, the Clinical Laboratory, the SPF Animal Laboratory andtheBioinformatics Platform.The center covers an
area of about 2000 m2, the value is worth over 50 million RMB. Now, the Public Laboratory is not only an important experimental base for conducting scientific research and translational medicine research, but also a supporting
platform for cultivating top-notch creative medical talent.
</p>
...
...
@@ -387,70 +514,42 @@
<img src="../images/ins_2.png" alt="" srcset="">
<p>
1. The core facility and technical service platform is funded by Tianjin medical university
cancer institute & hospital. The establishment of this platform will provide centralized and
expertise support to our colleagues requiring these advanced technology platforms in their
research studies. It will enhance effective usage of resources and maximize the use of
expensive instruments required for these advanced technology platforms. The platform is
equipped with Laser Scanning Confocal Microscope, Flow Cytometer, Upright Fluorescent
Microscope, Inverted Fluorescent Microscope, Real-Time PCR apparatus, Ultra-Centrifuge and
so on.The appointments software (LIMS) has been used deeply along with the servicesto
enhance service abilityand to improve the service efficiency.
1. The core facility and technical service platform is funded by Tianjin medical university cancer institute & hospital. The establishment of this platform will provide centralized and expertise support to our colleagues requiring these advanced technology
platforms in their research studies. It will enhance effective usage of resources and maximize the use of expensive instruments required for these advanced technology platforms. The platform is equipped with Laser Scanning
Confocal Microscope, Flow Cytometer, Upright Fluorescent Microscope, Inverted Fluorescent Microscope, Real-Time PCR apparatus, Ultra-Centrifuge and so on.The appointments software (LIMS) has been used deeply along with the
servicesto enhance service abilityand to improve the service efficiency.
</p>
<img src="../images/ins_3.png" alt="" srcset="">
<p>
2. The clinical laboratory is a research platform for translational medicine. The objective
of the clinical laboratory is to provide multidisciplinary scientists from different faculty
of TJMUCH a synergistic platform which efficiently and effectively translate basic
scientific findings into knowledge that benefits patients, which is often described as an
effort to carry scientific knowledge ‘from bench to bedside’. At present, we have 17
different research groups at the clinical laboratory, all of which engage in cutting-edge
research. The research group (under the management of principal investigator) is a group of
researchers or students from the same faculty working together on a particular issue or
topic. In this way we hope to stretch boundaries, challenge traditional ways of thinking,
and innovate towards finding new solutions to problems. Now, the clinical laboratory is home
to world-class research facilities, a specialist clinical trials unit and a suite of
molecular biology laboratories.
2. The clinical laboratory is a research platform for translational medicine. The objective of the clinical laboratory is to provide multidisciplinary scientists from different faculty of TJMUCH a synergistic platform which efficiently and effectively
translate basic scientific findings into knowledge that benefits patients, which is often described as an effort to carry scientific knowledge ‘from bench to bedside’. At present, we have 17 different research groups at the
clinical laboratory, all of which engage in cutting-edge research. The research group (under the management of principal investigator) is a group of researchers or students from the same faculty working together on a particular
issue or topic. In this way we hope to stretch boundaries, challenge traditional ways of thinking, and innovate towards finding new solutions to problems. Now, the clinical laboratory is home to world-class research facilities,
a specialist clinical trials unit and a suite of molecular biology laboratories.
</p>
<img src="../images/ins_4.png" alt="" srcset="">
<p>
3. The SPF Animal Laboratory, with a total floor area of about 500 m2, is a comprehensive
service entity involved in research of Laboratory Animal Science, providing technical
support and services for animal research. It includes SPF (Specific-pathogen-free) barrier
environment, conventional environment and functional auxiliary environment. Relevant
environmental facilities obtained the experimental animal use license (SYXK (Tianjin)
2012-0005) issued by Tianjin Municipal Science and Technology Commission in 2012, and
successfully replaced the new experimental animal use license (SYXK (Tianjin) 2017-0005) in
2017, providing a strong guarantee for the scientific research of our discipline.Our staff
provides daily animal care for the 15,000 animals used in research and teaching
hospital-wide. Our goal remains to support the needs of our biomedical research community by
providing an optimal environment for their animals and research.
3. The SPF Animal Laboratory, with a total floor area of about 500 m2, is a comprehensive service entity involved in research of Laboratory Animal Science, providing technical support and services for animal research. It includes SPF (Specific-pathogen-free)
barrier environment, conventional environment and functional auxiliary environment. Relevant environmental facilities obtained the experimental animal use license (SYXK (Tianjin) 2012-0005) issued by Tianjin Municipal Science
and Technology Commission in 2012, and successfully replaced the new experimental animal use license (SYXK (Tianjin) 2017-0005) in 2017, providing a strong guarantee for the scientific research of our discipline.Our staff provides
daily animal care for the 15,000 animals used in research and teaching hospital-wide. Our goal remains to support the needs of our biomedical research community by providing an optimal environment for their animals and research.
</p>
<img src="../images/ins_5.png" alt="" srcset="">
<p>
4. Our research focuses on characterizing mutational landscape of human gastrointestinal
cancer, elucidating the association between mutational footprints and environmental factors,
identifying biomarkers with translational significance in immunotherapy and early cancer
diagnosis, and interpreting medical imaging data using deep learning algorithms. Through
bioinformatics analyses, we identified new driver genes underlying the development of
gastrointestinal cancer, and shed new lights on genetic markers that are potentially
clinically actionable. By applying deep learning algorithm to analyze large-scale
sonographic imaging data, we developed a deep learning model that could augment
radiologists’ ability in thyroid cancer diagnosis. We have published more than 20
peer-reviewed articles in international journals, including Lancet Oncology, JAMA Oncology,
and Annals of Oncology etc.
4. Our research focuses on characterizing mutational landscape of human gastrointestinal cancer, elucidating the association between mutational footprints and environmental factors, identifying biomarkers with translational significance in immunotherapy
and early cancer diagnosis, and interpreting medical imaging data using deep learning algorithms. Through bioinformatics analyses, we identified new driver genes underlying the development of gastrointestinal cancer, and shed
new lights on genetic markers that are potentially clinically actionable. By applying deep learning algorithm to analyze large-scale sonographic imaging data, we developed a deep learning model that could augment radiologists’
ability in thyroid cancer diagnosis. We have published more than 20 peer-reviewed articles in international journals, including Lancet Oncology, JAMA Oncology, and Annals of Oncology etc.
</p>
</div>
</div>
</div>
</div> -->
</div>
<footerclass="footer-content">
<divclass="footer-main">
<ulclass="list-unstyled third-ul">
<li>West Huan-Hu Rd, Ti Yuan Bei, Hexi District</li>
Tianjin Cancer Institute<span>></span>About Us<span>></span>Leadership
</div>
<divclass="contant">
<divclass="contant_top">
<divclass="contant_img">
<imgsrc="../images/30.png"alt=""/>
</div>
<divclass="sec_paixu">
<divclass="sec_show"style="width: 430px">
<divclass="img_text">
<divclass="img_text_imagebox">
<imgsrc="../images/4-1-2-2.png"alt=""srcset="">
</div>
<divclass="img_text_textbox">
Professor Yinguo Guang
Deputy Director,TCI
Chair,Department of Cancer Cell Biology
</div>
</div>
</div>
<divclass="sec_show"style="width: 400px">
<divclass="img_text">
<divclass="img_text_imagebox">
<imgsrc="../images/4-1-2-3.png"alt=""srcset="">
</div>
<divclass="img_text_textbox">
Professor Niurui Fang
Deputy Director,TCI
Chair, Department of Public Laboratory
<divclass="contant_word">
<divclass="contant_name">
Professor Xishan Hao
</div>
<divclass="contant_names">
Director
</div>
</div>
<divclass="sec_show"style="width: 400px">
<divclass="img_text">
<divclass="img_text_imagebox">
<imgsrc="../images/4-1-2-4.png"alt=""srcset="">
</div>
<divclass="img_text_textbox">
Professor Hui Li
Deputy Director,TCI
Chair, Department of Gastrointestinal Cancer Biology
</div>
<divclass="contant_names">
Tianjin Cancer Institute
</div>
</div>
<divclass="contant_center">
Chairman of The Professional Committee of Clinical Application, China Medicinal Biotech Association; Editor-in-Chief of 《 Chinese Journal of Clinical Oncology 》 and 《 Cancer Biology &Medicine 》 . Vice President of Serologic International Society (SIS);
Honorary President of Tianjin Medical University; Honorary President of Tianjin Medical University Cancer Institute & Hospital, Honorary President of CACA; <br/>Professor Xishan Hao is a leading surgical oncologist
in China. He devoted himself to the clinical oncology and scientific research of cancer for more than 40 years and made many innovative achievements in surgical oncology, immunotherapy and epidemiology of cancer.
</div>
</div>
</div>
<!-- 形象墙 -->
<divclass="contant_bottom"></div>
</div>
<footerclass="footer-content">
<divclass="footer-main">
<ulclass="list-unstyled third-ul">
<li>West Huan-Hu Rd, Ti Yuan Bei, Hexi District</li>
Tianjin Cancer Institute<span>></span>Research<span>></span>Our Researchers
</div>
<divclass="contant">
<divclass="contant_top">
<divclass="contant_top_img">
<imgsrc="../images/lixiangchun.png"alt="">
</div>
<divclass="contant_top_word">
<divclass="contant_name">
Prof. Xiangchun Li
</h4>
<h4class="pername"style="white-space: nowrap">
</div>
<divclass="contant_name">
Professor of Department of Public Laboratory
</h4>
</div>
</div>
<divclass="depart_introduce">
<divclass="part_desc">
<pstyle="font-size: 18px">
<h3>Educaiton</h3><br>
2006.9-2010.7 Bachelor of Engineering in Bioinformation Technology, Huazhong University
of Science and Technology, <br>
2012.8~2016.12 Ph.D in Medical Sciences, Chinese University of Hong Kong,
Professional Experiences： <br>
2010.7~2012.8 NGS data analyst, Beijing Genomics Institute, Shenzhen,
2017.2~present Professor, Tianjin Cancer Institute, Tianjin Medical University Cancer
Institute and Hospital,
</div>
</div>
</div>
<divclass="contant_center">
<h3>Educaiton</h3> 2006.9-2010.7 Bachelor of Engineering in Bioinformation Technology, Huazhong University of Science and Technology, <br> 2012.8~2016.12 Ph.D in Medical Sciences, Chinese University of Hong Kong, Professional Experiences：
<br> 2010.7~2012.8 NGS data analyst, Beijing Genomics Institute, Shenzhen, 2017.2~present Professor, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute and Hospital,
<h3>Research Focus</h3>
<br>
Our research focuses on characterizing mutational landscape of human gastrointestinal
cancer, elucidating the association between mutational footprints and environmental
factors, identifying biomarkers with translational significance in immunotherapy and
early cancer diagnosis, and interpreting medical imaging data using deep learning
algorithms. Through bioinformatics analyses, we identified new driver genes underlying
the development of gastrointestinal cancer, and shed new lights on genetic markers that
are potentially clinically actionable. By applying deep learning algorithm to analyze
large-scale sonographic imaging data, we developed a deep learning model that could
augment radiologists’ ability in thyroid cancer diagnosis. We have published more than 20
peer-reviewed articles in international journals, including Lancet Oncology, JAMA
Oncology, and Annals of Oncology etc. <br>
Our research focuses on characterizing mutational landscape of human gastrointestinal cancer, elucidating the association between mutational footprints and environmental factors, identifying biomarkers with translational significance in immunotherapy
and early cancer diagnosis, and interpreting medical imaging data using deep learning algorithms. Through bioinformatics analyses, we identified new driver genes underlying the development of gastrointestinal cancer, and shed new lights
on genetic markers that are potentially clinically actionable. By applying deep learning algorithm to analyze large-scale sonographic imaging data, we developed a deep learning model that could augment radiologists’ ability in thyroid
cancer diagnosis. We have published more than 20 peer-reviewed articles in international journals, including Lancet Oncology, JAMA Oncology, and Annals of Oncology etc. <br>
<h3>Selected Publications</h3>
<br>
1. Li X#, Zhang S#, Zhang Q#, Wei X#, Pan Y, Zhao J, Xin X, Qin C, Wang X, Li J, Yang F,
Zhao Y, Yang M, Wang Q, Zheng Z, Zheng X, Yang X, Whitlow CT, Gurcan MN, Zhang L, Wang X,
Pasche BC, Gao M, Zhang W*, Chen K*. Diagnosis of thyroid cancer using deep convolutional
neural network models applied to sonographic images: a retrospective, multicohort,
diagnostic study. Lancet Oncol. 2018 Dec 21;. doi: 10.1016/S1470-2045(18)30762-9. [Epub
ahead of print] PubMed PMID: 30583848. <br>
2. Li X#, Pasche B, Zhang W*, Chen K*. Association of MUC16 Mutation With Tumor Mutation
Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018 Dec
1. Li X#, Zhang S#, Zhang Q#, Wei X#, Pan Y, Zhao J, Xin X, Qin C, Wang X, Li J, Yang F, Zhao Y, Yang M, Wang Q, Zheng Z, Zheng X, Yang X, Whitlow CT, Gurcan MN, Zhang L, Wang X, Pasche BC, Gao M, Zhang W*, Chen K*. Diagnosis of thyroid cancer using deep
convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study. Lancet Oncol. 2018 Dec 21;. doi: 10.1016/S1470-2045(18)30762-9. [Epub ahead of print] PubMed PMID: 30583848. <br> 2. Li X#, Pasche B, Zhang W*, Chen K*. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018 Dec 1;4(12):1691-1698. doi: 10.1001/jamaoncol.2018.2805. PubMed PMID: 30098163.
3. Li X#, Wang MY, Yang M, Dai HJ, Zhang BF, Wang W, Chu XL, Wang X, Zheng H, Niu RF, Zhang W*, Chen KX*. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal
squamous cell carcinoma. Ann Oncol. 2018 Apr 1;29(4):938-944. doi: 10.1093/annonc/mdy011. PubMed PMID: 29351612; PubMed Central PMCID: PMC5913594. <br> 4. Chen K#, Yang D#, Li X#, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H,
Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK*, Zhang W*, Hao X*. Mutational landscape of
gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. doi: 10.1073/pnas.1422640112. Epub 2015 Jan 12. PubMed PMID: 25583476; PubMed Central PMCID: PMC4313862.
<br> 5. Song Y#, Li L#, Ou Y#, Gao Z#, Li E#, Li X#, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, Huang X, Fan J, Dong L, Chen G, Ma L, Yang J, Chen L, He M, Li M, Zhuang X, Huang K, Qiu K, Yin G, Guo G, Feng Q, Chen P, Wu Z,
Wu J, Ma L, Zhao J, Luo L, Fu M, Xu B, Chen B, Li Y, Tong T, Wang M, Liu Z, Lin D, Zhang X, Yang H, Wang J, Zhan Q*. <br> Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014 May 1;509(7498):91-5.
doi: 10.1038/nature13176. Epub 2014 Mar 16. PubMed PMID: 24670651. 6. Wang M#, Yang C#, Zhang X, Li X*. Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Mol Genet Genomics. 2018 Jun;293(3):737-746.
doi: 10.1007/s00438-018-1416-7. Epub 2018 Jan 12. PubMed PMID: 29330617.
<br> 7. Ho J#, Li X#, Zhang L#, Liang Y, Hu W, Yau JCW, Chan H, Gin T, Chan MTV*, Tse G*, Wu WKK*. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. Semin Cancer Biol. 2018 Apr 25;.
doi: 10.1016/j.semcancer.2018.04.004. [Epub ahead of print] Review. PubMed PMID: 29705685. 8. Wang X#, Li X#, Zhang L#, Wong SH, Wang MHT, Tse G, Dai RZW, Nakatsu G, Coker OO, Chen Z, Ko H, Chan JYK, Liu T, Cheng CHK, Cheng ASL, To
KF, Plewczynski D, Sung JJY, Yu J, Gin T*, Chan MTV*, Wu WKK*. Oncogenes expand during evolution to withstand somatic amplification. Ann Oncol. 2018 Nov 1;29(11):2254-2260. doi: 10.1093/annonc/mdy397. PubMed PMID: 30204835. <br> 9.
Li X#, Xu W#, Kang W, Wong SH, Wang M, Zhou Y, Fang X, Zhang X, Yang H, Wong CH, To KF, Chan SL, Chan MTV, Sung JJY, Wu WKK*, Yu J*. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics.
2018;8(6):1740-1751. doi: 10.7150/thno.22010. eCollection 2018. PubMed PMID: 29556353; PubMed Central PMCID: PMC5858179. <br> 10. Wu WK#, Li X#, Wang X#, Dai RZ, Cheng AS, Wang MH, Kwong T, Chow TC, Yu J*, Chan MT*, Wong SH*. Oncogenes
without a Neighboring Tumor-Suppressor Gene Are More Prone to Amplification. Mol Biol Evol. 2017 Apr 1;34(4):903-907. doi: 10.1093/molbev/msw295. PubMed PMID: 28087780; PubMed Central PMCID: PMC5400371. <br> 11. Li X#, Wu WK*, Xing
R, Wong SH, Liu Y, Fang X, Zhang Y, Wang M, Wang J, Li L, Zhou Y, Tang S, Peng S, Qiu K, Chen L, Chen K, Yang H, Zhang W, Chan MT, Lu Y, Sung JJ, Yu J*. Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include
Novel Mutational Signatures with Prognostic Capability. Cancer Res. 2016 Apr 1;76(7):1724-32. doi: 10.1158/0008-5472.CAN-15-2443. Epub 2016 Feb 8. PubMed PMID: 26857262. <br> 12. Nakatsu G#, Li X#, Zhou H#, Sheng J#, Wong SH#, Wu WK#,
Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J*, Sung JJ*. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015 Oct 30;6:8727. doi: 10.1038/ncomms9727. PubMed PMID:
26515465; PubMed Central PMCID: PMC4640069. <br> 13. Li C#, Gao Z#, Li F#, Li X#, Sun Y, Wang M, Li D, Wang R, Li F, Fang R, Pan Y, Luo X, He J, Zheng L, Xia J, Qiu L, He J, Ye T, Zhang R, He M, Zhu M, Hu H, Shi T, Zhou X, Sun M, Tian
S, Zhou Y, Wang Q, Chen L, Yin G, Lu J, Wu R, Guo G, Li Y, Hu X, Li L, Asan, Wang Q, Yin Y, Feng Q, Wang B, Wang H, Wang M, Yang X, Zhang X, Yang H, Jin L, Wang CY, Ji H*, Chen H*, Wang J , Wei Q*. Whole Exome Sequencing Identifies
Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Sci Rep. 2015 Oct 27;5:14237. doi: 10.1038/srep14237. PubMed PMID: 26503331; PubMed Central PMCID: PMC4621504. <br> 14. Yu
J#*, Wu WK# Li X#, He J, Li XX, Ng SS, Yu C, Gao Z, Yang J, Li M, Wang Q, Liang Q, Pan Y, Tong JH, To KF, Wong N, Zhang N, Chen J, Lu Y, Lai PB, Chan FK, Li Y, Kung HF, Yang H, Wang J*, Sung JJ*. Novel recurrently mutated genes and
a prognostic mutation signature in colorectal cancer. Gut. 2015 Apr;64(4):636-45. doi: 10.1136/gutjnl-2013-306620. Epub 2014 Jun 20. PubMed PMID: 24951259; PubMed Central PMCID: PMC4392212.
<h3>Selected Research
</h3> ProjectsDiagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicolor, diagnostic study
